Acutus Medical, Inc. - Common Stock, par value $0.001 per share (AFIB)

CUSIP: 005111109

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
60,359,615
Total 13F shares
2,000
Share change
0
Total reported value
$4
Price per share
$0.00
Number of holders
1

Quarterly Holders Quick Answers

What is CUSIP 005111109?
CUSIP 005111109 identifies AFIB - Acutus Medical, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of AFIB - Acutus Medical, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
James E. Flynn
3/4/5 13D/G
Director, Director by deputization
9.1%
from 13D/G
5,434,049
mixed-class rows
$4,163,964 27 Jan 2025
ORBIMED ADVISORS LLC
3/4/5
Director, 10%+ Owner
class O/S missing
1,677,361
$2,616,683 19 Jul 2021
Shahzad Malik
3/4/5
Director
mixed-class rows
1,562,757
mixed-class rows
$2,426,946 17 Jun 2021
James F. Hinrichs.
3/4/5
Director
mixed-class rows
95,910
mixed-class rows
$119,043 16 Jun 2022
R. Scott Huennekens
3/4/5
Director
class O/S missing
529,349
$100,047 15 Jun 2023
Vincent J. Burgess
3/4/5
Chief Executive Officer, Director
class O/S missing
61,469
$95,892 01 Apr 2022
Steven McQuillan
3/4/5
SVP, Clinical Affairs & QA
class O/S missing
45,844
$71,517 01 Apr 2022
David Roman
3/4/5
President & CEO
class O/S missing
332,134
$62,773 07 Jan 2024
Tom Sohn
3/4/5
SVP, Gen. Counsel & Secretary
class O/S missing
105,009
$18,167 06 Feb 2024
Daniella Cramp
3/4/5
Director
mixed-class rows
31,223
mixed-class rows
$18,132 16 Jun 2022
Charlie Piscitello
3/4/5
SVP, Chief People Officer
class O/S missing
85,683
$16,194 01 Apr 2023
Takeo Mukai
3/4/5
CFO
class O/S missing
72,874
$15,304 01 Mar 2024
Kevin Mathews
3/4/5
SVP, Commercial
class O/S missing
61,106
$11,549 07 Jan 2024
John F. Sheridan
3/4/5
Director
class O/S missing
24,347
$4,602 15 Jun 2023
Jason K. Garland
3/4/5
Director
class O/S missing
22,400
$4,234 15 Jun 2023
Niamh Louise Pellegrini
3/4/5
Director
class O/S missing
20,972
$3,964 15 Jun 2023
Andrew ElBardissi
3/4/5
Director
class O/S missing
20,822
$3,935 15 Jun 2023
David P. Bonita
3/4/5
Director
class O/S missing
20,822
$3,935 15 Jun 2023
Shaden Marzouk
3/4/5
Director
class O/S missing
20,822
$3,935 15 Jun 2023
S.A. Mason LLC
13F
Company
0%
2,000
$85 31 Mar 2025
13F

Institutional Holders of Acutus Medical, Inc. - Common Stock, par value $0.001 per share (AFIB) as of Q2 2025

As of 30 Jun 2025, Acutus Medical, Inc. - Common Stock, par value $0.001 per share (AFIB) was held by 1 institutional shareholder that filed Form 13F with the SEC. Together, they reported ownership of 2,000 shares. The largest 1 holders included S.A. Mason LLC. This page lists 1 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
1
Q2 2025 holders
1
Holder diff
0
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 Value $ Q2 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .